|
Eligo Bioscience's management team from left: CEO Xavier Duportet, PhD, Chief Business Officer, Aurélie Grienenberger, PhD, and CSO David Bikard, PhD
In funding news, Senti Biosciences announced a $105 million Series B financing round led by Leaps by Bayer to engineer gene circuits that improve cell and gene therapy products. “We believe that synthetic biology will become an important pillar in next-generation cell and gene therapy, and that Senti Bio’s leadership in designing and optimizing biological circuits fits precisely with our ambition to prevent and cure cancer and to regenerate lost tissue function,” said Juergen Eckhardt, MD, Head of Leaps by Bayer, in a recent press release.
Air Protein announced a $32 Million series A funding round to transform carbon dioxide into meat-free meat. Check out our previous conversation with CEO Lisa Dyson about how her company's platform seeks to address both hunger and climate change through carbon negative food.
|
